Current Development, Obstacle and Futural Direction of Induced Pluripotent Stem Cell and Mesenchymal Stem Cell Treatment in Degenerative Retinal Disease

Int J Mol Sci. 2022 Feb 25;23(5):2529. doi: 10.3390/ijms23052529.

Abstract

Degenerative retinal disease is one of the major causes of vision loss around the world. The past several decades have witnessed emerging development of stem cell treatment for retinal disease. Nevertheless, sourcing stem cells remains controversial due to ethical concerns and their rarity. Furthermore, induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs) are both isolated from patients' mature tissues; thus, issues such as avoiding moral controversy and adverse events related to immunosuppression and obtaining a large number of cells have opened a new era in regenerative medicine. This review focuses on the current application and development, clinical trials, and latest research of stem cell therapy, as well as its limitations and future directions.

Keywords: induced pluripotent stem cells; mesenchymal stem cell; retinal disease; review article.

Publication types

  • Review

MeSH terms

  • Humans
  • Induced Pluripotent Stem Cells*
  • Mesenchymal Stem Cells*
  • Regenerative Medicine
  • Retinal Diseases* / therapy
  • Stem Cell Transplantation